Norqia Digest selects medical research, explains what studies found and where their limits are, and makes room for carefully reviewed community perspectives. Read professional or plain-language editions.
Four studies, two reading levels. This first issue focuses on cystic fibrosis; future coverage is not limited to CF.
Researchers in Canada studied 146 people with cystic fibrosis (CF) before and after one year of taking a drug called elexacaftor/tezacaftor/ivacaftor - often shortened to ETI, a…
Read the summaryResearchers linked two large databases - one tracking CF patients across the US and one tracking hospital visits at children's hospitals - to study more than 8,000 children with CF…
Read the summaryThis study used data from the US CF Foundation Patient Registry, covering roughly 12,000 to 16,000 people with CF each year from 2011 to 2019, to ask whether inhaled antibiotic therapy…
Read the summaryA Dutch study of 43 people with CF - both children and adults - looked at how well patients were taking their medicines using three different approaches: checking pharmacy records to…
Read the summaryIn a Canadian observational study, three work-productivity measures improved over one year among 75 employed participants. The before-and-after design cannot establish that ETI alone caused the change.
Read the study summary
Norqia Digest is curated by Alexander Elbert, PhD. AI can assist analysis and drafting; the editor reviews the material. Each research story links back to its original publication. Read the editorial approach or send feedback.